Health Canada approves XERMELO™ (telotristat ethyl)

Health Canada approves XERMELO™ (telotristat ethyl) for the treatment of adult patients suffering from refractory carcinoid syndrome diarrhea(1) "XERMELOTM is a novel, orally administered, inhibitor of the enzyme tryptophan hydroxylase [...]

By |2018-10-17T14:45:09-04:00October 17th, 2018|Treatment News|Comments Off on Health Canada approves XERMELO™ (telotristat ethyl)
Go to Top